title: Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle.
abstract: Ranolazine is an novel investigational antianginal agent that stimulates glucose oxidation in isolated rat hearts. This study determined its effects on metabolic substrate and O2 utilization in an in vitro skeletal muscle preparation, the rat epitrochlearis muscle. Muscles were superfused with Krebs-Henseleit buffer containing 3% albumin, 0.4 mM palmitate, 5.5 mM glucose, 0.5 mM lactate, and a physiological amino acid mixture. Perfusate also contained either 1) [U-14C]glucose for measurement of glucose oxidation or 2) [9,10-3H]palmitate and [U-14C]lactate for measurement of palmitate and lactate oxidation. Addition of ranolazine (10 microM) significantly stimulated glucose oxidation and decreased palmitate oxidation but had no effect on lactate oxidation. Overall, the calculated relative contribution of glucose oxidation to aerobic ATP production increased from 12 to 33%, whereas from palmitate it decreased from 55 to 26%. Ranolazine did not alter tissue malonyl-CoA contents, making it unlikely that the decrease in palmitate oxidation caused by ranolazine is due to a decrease in the activity of acetyl-CoA carboxylase. These data demonstrate that ranolazine can shift energy substrate preference in skeletal muscle, which could potentially prove useful in ischemic disorders of skeletal muscle.
authors.affiliation: Department of Pharmacology, Syntex Research Centre, Edinburgh, Scotland, United Kingdom.
authors.forename: J G
authors.initials: JG
authors.lastname: McCormack
authors.forename: V E
authors.initials: VE
authors.lastname: Baracos
authors.forename: R
authors.initials: R
authors.lastname: Barr
authors.forename: G D
authors.initials: GD
authors.lastname: Lopaschuk
mesh_terms: D000083:Acetanilides; D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D004734:Energy Metabolism / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D066298:In Vitro Techniques; D007511:Ischemia / Q000378:metabolism; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D019344:Lactic Acid / Q000097:blood; D008297:Male; D008316:Malonyl Coenzyme A / Q000378:metabolism; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D010101:Oxygen Consumption / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D000069458:Ranolazine; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000083:Acetanilides; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D007527:Isoenzymes; D010879:Piperazines; D019344:Lactic Acid; D008316:Malonyl Coenzyme A; D000255:Adenosine Triphosphate; D000069458:Ranolazine; D000103:Acetyl-CoA Carboxylase; D005947:Glucose